Ombrez

Uses

Ombrez is used for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Ombrez is a long-acting β2-adrenergic agonist used for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Ombrez is also used to associated treatment for these conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Maintenance

How Ombrez works

Ombrez works by stimulating adrenergic beta-2 receptors in the smooth muscle of the airways. This causes relaxation of the muscle, thereby increasing the diameter of the airways, which become constricted in asthma and COPD. It is also long acting due to its high affinity to the lipid raft domains in the airway membrane so it slowly dissociates from the receptors. Ombrez also has a high intrinsic efficacy so it is also very rapid acting - onset of action occurs within 5 minutes.

The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of these findings is unknown.

Dosage

Ombrez dosage

Ombrez capsules must not be swallowed as the intended effects on the lungs will not be obtained. The contents of Ombrez capsules are only for oral inhalation and should only be used with thedevice.

The recommended dosage of Ombrez is the once-daily inhalation of the contents of one 75/150 mcg Ombrez capsule using the device.

Ombrez should be administered once daily every day at the same time of the day by the orally inhaled route only. If a dose is missed, the next dose should be taken as soon as it is remembered. Do not use Ombrez more than one time every 24 hours.

Side Effects

The most commonly reported adverse effects were cough, nasopharyngitis, headache, nausea, oropharyngeal pain. Some other also reported of hypersensitivity reactions, paradoxical bronchospasm, tachycardia, pruritis and dizziness.

Toxicity

The expected signs and symptoms associated with overdosage of indacaterol are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of indacaterol.

Precaution

Rarely, serious (sometimes fatal) breathing problems have happened to people with asthma using a long-acting inhaled beta agonist (salmeterol). Since Ombrez is similar to salmeterol, it might cause these serious breathing problems. Ombrez has not been shown to be safe or effective to treat asthma and is not approved for this use.

Interaction

Ombrez shows interaction with Adrenergic Drugs, Xanthine Derivatives, Steroids, or Diuretics. Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of Ombrez. The ECG changes or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β2-agonists. Ombrez, as with other β2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs known to prolong the QTc interval. β-adrenergic receptor antagonists (beta-blockers) and Ombrez may interfere with the effect of each other when administered concurrently.

Food Interaction

Ombrez Hypertension interaction

[Moderate] Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).

Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.

However, beta-2-selectivity is not absolute and can be lost with larger doses.

High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.

Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and

The recommended dosages should not be exceeded.

Ombrez Drug Interaction

Moderate: umeclidinium / vilanterol, fluticasone / vilanterol, albuterol / ipratropium, albuterolUnknown: charcoal, bifidobacterium infantis, ipratropium, amoxicillin / clavulanate, dicyclomine, multivitamin with minerals, tadalafil, loratadine, fentanyl, sodium iodide, atorvastatin, acetaminophen, tiotropium, tiotropium, cyanocobalamin, ascorbic acid

Ombrez Disease Interaction

Moderate: cardiovascular, diabetes, hypokalemia, seizures

Volume of Distribution

After intravenous infusion the volume of distribution (Vz) of indacaterol was 2,361 L to 2,557 L indicating an extensive distribution.

Elimination Route

The median time to reach peak serum concentrations of indacaterol was approximately 15 minutes after single or repeated inhaled doses. Absolute bioavailability of indacaterol after an inhaled dose was on average 43-45%.

Half Life

Ombrez serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.

Clearance

Renal clearance of indacaterol is, on average, between 0.46 and 1.2 L/h. Serum clearance of indacaterol is 18.8 L/h to 23.3 L/h.

Elimination Route

Renal clearance plays a minor role (about 2 to 6% of systemic clearance) in the elimination of systemically available indacaterol. In a human ADME study where indacaterol was given orally, the fecal route of excretion was dominant over the urinary route. Ombrez was excreted into human feces primarily as unchanged parent drug (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose).

Pregnancy & Breastfeeding use

Pregnancy Category C. There are no adequate and well-controlled studies with Ombrez powder in pregnant women. Ombrez powder should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known that the active component of Ombrez powder, Ombrez is excreted in human milk. Because many drugs are excreted in human milk and because Ombrez has been detected in the milk of lactating rats, caution should be exercised when Ombrez powder is administered to nursing women.

Contraindication

All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication. Ombrez powder is not indicated for the treatment of asthma. Ombrez is contraindicated in patients with a history of hypersensitivity to Ombrez or to any of the ingredients.

Special Warning

Geriatric patients: No dosage adjustment is required for geriatric patients, patients with mild and moderate hepatic impairment, or renal impaired patients.

Hepatic impairment: No data are available for subjects with severe hepatic impairment.

Hepatic use: Not indicated for use in the hepatic impairment. Safety and efficacy have not been established.

Acute Overdose

The expected signs and symptoms associated with over dosage of Ombrez powder are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an over dose of Ombrez powder.

Storage Condition

Ombrez capsules must always be stored in the blister, and only removed immediately before use. Keep in a cool & dry place. Keep out of the reach of children.

Innovators Monograph

You find simplified version here Ombrez